Filing Flows › Corcept Therapeutics (CORT) › Net income
Corcept Therapeutics (CORT) net income by quarter
Corcept Therapeutics' net income was $127M in Q3 2026 (third quarter 2026), +195% from Q2 2026. Over the last 6 quarters it ranged from $19.7M (Q3 2025) to $127M (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $127M | +195% | +545% |
| Q2 2026 | $43.0M | +77% | +22% |
| Q4 2025 | $24.3M | +23% | — |
| Q3 2025 | $19.7M | -44% | — |
| Q2 2025 | $35.1M | +71% | — |
| Q1 2025 | $20.5M | — | — |
Q3 2026 at a glance
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
What is Corcept Therapeutics' net income?
Corcept Therapeutics' net income was $127M in Q3 2026 (third quarter 2026), +195% from Q2 2026.
How has Corcept Therapeutics' net income changed?
Over the last 6 quarters it ranged from $19.7M (Q3 2025) to $127M (Q3 2026).